BLB&B Advisors’s Elicio Therapeutics ELTX Stock Holding History

BLB&B Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,550	Closed	-$8.99K	–	244
2023 Q1	$8.99K	Hold	1,550	–	–	﹤0.01%	235
2022 Q4	$12.6K	Sell	1,550 -750	-33%	-$6.81K	﹤0.01%	235
2022 Q3	$21K	Sell	2,300 -3,385	-60%	-$35.4K	﹤0.01%	229
2022 Q2	$65K	Hold	5,685	–	–	0.01%	241
2022 Q1	$121K	Hold	5,685	–	–	0.01%	247
2021 Q4	$165K	Hold	5,685	–	–	0.01%	250
2021 Q3	$555K	Hold	5,685	–	–	0.04%	174
2021 Q2	$740K	Buy	+5,685	New	+$820K	0.05%	143

Other funds holding ELTX

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MHC

Meyer Handelman Company Rye Brook, New York $3.53B AUM 30.49% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BLB&B Advisors's ELTX Position: Q2 2023 in Review

BLB&B Advisors sold out of Elicio Therapeutics (ELTX) in Q2 2023, closing a stake of 1,550 shares — an estimated $8.99K sold.

BLB&B Advisors first reported a position in ELTX in Q2 2021 and held it in 8 quarters. The position peaked at $740K in Q2 2021. 15 funds tracked by Wall St. Rank hold ELTX as of Q2 2023.

BLB&B Advisors reported no remaining Elicio Therapeutics position as of Q2 2023 after selling out during the quarter.
BLB&B Advisors sold 1,550 Elicio Therapeutics shares in Q2 2023, an estimated $8.99K.
BLB&B Advisors first reported a position in Elicio Therapeutics in Q2 2021 and held it in 8 quarters.
BLB&B Advisors's Elicio Therapeutics position peaked at $740K in Q2 2021.
15 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2023.

Based on BLB&B Advisors's 13F filing for Q2 2023, filed 20 Jul 2023.